Breaking News

Sterling Pharma Solutions Granted MIA (IMP) License for cGMP Antibody-Drug Conjugate Manufacturing Facility

The license allows for GMP bulk drug substance manufacturing to support all phases of clinical studies.

Sterling Pharma Solutions, a global contract development and manufacturing organization (CDMO), has been granted a Manufacturer’s Authorization for Investigational Medicinal Products from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). The license allows Sterling to manufacture antibody-drug conjugates (ADCs) for clinical use in its current good manufacturing practices (cGMP) compliant manufacturing facility in Deeside, UK. Sterling acquired the 6,500 square-meter-s...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters